Bristol-myers Squibb Compnay

Morphochem Gmbh

Small Molecule Therapeutics, Inc.

Rolf Menzel

Scott T Taylor

Tamotsu Furumai

Weihong Hsing

Pamela A Taggart

Keiichi Numata

David A Elsemore

Mitsuaki Tsunakawa

The present invention relates to methods and compositions for the identification and modulation of protein-protein interactions. Specifically, the invention relates to methods and compositions for efficient, sensitive, high-throughput CadC-based screens for the identification of peptides involved in protein-protein interactions, including, but not limited to, peptides comprising amino acid sequences involved in receptor dimerization. The invention further relates to methods and compositions for efficient, sensitive, high-throughput CadC-based screens for compounds which modulate protein-protein interactions, such as, for example, modulation of interactions between protein sequences involved in receptor interactions, e.g., dimerization.

Methods and compositions for identifying and modulating ctionprotein-interactions

The present invention relates to methods and compositions for the modulation of bacterial topoisomerase enzymes within bacterial cells. More specifically, the present invention relates to bacterial assays wherein the levels of bacterial topoisomerase enzymes or the levels of target sites within the enzymes are varied within bacterial test strains in order to screen for compounds that target, i.e., interact with the topoisomerase enzymes, causing DNA damage and hence, bacterial growth inhibition and/or cell death. The present methods and compositions are useful for the identification and characterization of novel therapeutic antibacterial compounds.

Methods and compositions for modulation of bacterial topoisomerase enzymes

Periplasmic membrane-bound system for detecting protein-protein

Expression vectors for human topoisomerase I and a method for detecting poisons of human topoisomerase I. The vector preferably contains a promoter, DNA coding for human topoisomerase I, DNA coding for a selectable marker, an origin of replication, and lac I.sup.q DNA which encodes a repressor for the promoter.

Expression vector for human topoisomerase I

Hayumicin compounds, obtainable by cultivation of a strain of Actinomadura sp. designated ATCC 55432, and analogs of these compounds. The novel compounds have antitumor as well as antibiotic, particularly antibacterial, activity.

Antitumor antibiotic compounds: hayumicins and analogs thereof

Growing community of inventors

Yardley, PA, United States of America

Rolf Menzel